Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus

Abstract

This study, the first prospective study for cervical esophageal cancer, showed that CRT has sufficient efficacy and safety for use as an alternative to surgery for these patients.

Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: Comparison of failure pattern and toxicities between intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy

“…Patient characteristics and the results from previous reports are summarized in Table . There are 3 recent retrospective studies of IMRT for cervical esophageal cancer.…”

“…Patient characteristics and the results from previous reports are summarized in Table 5. 6,[8][9][10][11][17][18][19] There are 3 recent retrospective studies of IMRT for cervical esophageal cancer. Cao et al 8 reported 64 patients treated with definitive IMRT, with a median radiation dose of 64 Gy.…”

Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma

“…1 The treatments for esophageal cancer also vary, depending on their location, such as in the cervical or thoracic portion of the esophagus or at the gastroesophageal (GE) junction, according to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology and findings from previous studies. [2][3][4][5][6] The National Comprehensive Cancer Network guidelines describe various treatments for thoracic esophageal SCC (TESCC). 2 Surgery, definitive concurrent chemoradiotherapy (CCRT), and neoadjuvant CCRT followed by surgery (trimodality therapy) are the main therapies for TESCC.…”

A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer

“…Of note, they did not provide information on potential confounding factors, such as chemotherapeutic regimens and safety information. Furthermore, one Japanese phase 2 trial [42] was conducted in 2009-2013 in 30 patients with CEC to evaluate Cis-based high dose RT (60 Gy), demonstrating a remarkable 3-year OS of 67%, compared with 46% observed in this study. However, this concerned a highly selected patient group with mostly early stage disease and excellent performance status.…”